Nitric oxide synthesis inhibition attenuates haloperidol-induced supersensitivity

Journal of Psychiatry and Neuroscience

Volumn 22, Issue 1, 1997, Pages 61-64

  Pudiak, Cindy M ^a   Bozarth, Michael A ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

antipsychotic medication; cocaine; haloperidol; L NAME; locomotor activity; neuroleptics; nitric oxide; supersensitivity

Indexed keywords

COCAINE; DOPAMINE RECEPTOR; HALOPERIDOL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE;

ANIMAL EXPERIMENT; ARTICLE; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN;

ANIMALS; ANTIPSYCHOTIC AGENTS; COCAINE; DRUG HYPERSENSITIVITY; DRUG SYNERGISM; HALOPERIDOL; LOCOMOTION; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE;

EID: 0031049355     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Baldessarini RJ. 1990. Drugs and the treatment of psychiatric disorders. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. The pharmacological basis of therapeutics. New York: Pergamon Press. p 383-435.
2. Garthwaite J. 1991. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14:60-7.
3. Garthwaite J. 1993. Nitric oxide signalling in the nervous system. Semin Neurosci 5:171-80.
4. Kane JM, Smith JM. 1982. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473-81.
5. Karler R, Calder LD, Chaundhry IA, Turkanis SA. 1989. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci 45:599-606.
6. Kuribara H, Asami T, Ida I, Iijima Y, Tadokora S. 1992. Effect of repeated MK-801 on ambulation in mice and in sensitization following methamphetamine. Psychopharmacology 108:271-5.
7. LeDuc PA, Mittleman G. 1995. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology 121:407-27.
8. Meltzer HY, Schyve PM, Moore KE. 1986. Drugs for therapy of psychosis. In: Pradhan SN, Maickel RP, Dutta SN, editors. Pharmacology in medicine: principles and practice. Bethesda (MD): SP Press International. p 325-37.
9. Muller P, Seeman P. 1978. Dopaminergic supersensitivity after neuroleptics: time-course specificity. Psychopharmacology 60:1-11.
10. Pudiak CM, Bozarth MA. 1993. L-NAME and MK-801 attenuate sensitization to the locomotor-stimulating effect of cocaine. Life Sci 53:1517-24.
11. Robinson TE. 1988. Stimulant drugs and stress: factors influencing individual differences in the susceptibility to sensitization. In: Kalivas PW, Barnes CW, editors. Sensitization of the nervous system. Caldwell (NJ): Telford Press. p 145-73.
12. Robinson TE, Berridge KC. 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18:247-91.
13. Seeman P. 1995. Dopamine receptors and psychosis. Scientific American 2:28-37.
14. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D. 1974. Drugs, neurotransmitters, and schizophrenia. Science 184:1243-52.
15. Snyder SH, Bredt DS. 1992. Biological roles of nitric oxide. Scientific American 266:68-77.
16. Tarsy D. 1983. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 6(1 Suppl):9S-26S.
17. VonVoigtlander PF, Losey EG, Triezenberg HG. 1975. Increased sensitivity to dopaminergic agents after chronic neuroleptic treatment. J Pharmacol Exp Ther 193:88-94.